Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.
Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hum Pathol. 2020 Feb;96:48-55. doi: 10.1016/j.humpath.2019.11.001. Epub 2020 Jan 10.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma showing variable degrees of differentiation toward hepatocellular and cholangiocellular carcinoma. Its great heterogeneity in term of morphology, immunophenotype, molecular, radiological and clinical features represents a challenge still to overcome. The multidisciplinary 2018 International Consensus on the nomenclature of cHCC-CCA allowed to define key issues of this entity. Here we review the historical controversies of cHCC-CCA, resume the key elements of the 2018 consensus, now incorporated in the 2019 WHO classification, and propose a short survival guide to help surgical pathologists facing cHCC-CCA in their routine workup.
混合型肝细胞癌-胆管细胞癌(cHCC-CCA)是一种罕见的原发性肝癌,其向肝细胞癌和胆管细胞癌分化的程度不同。其在形态学、免疫表型、分子、影像学和临床特征方面具有很大的异质性,这仍然是一个有待克服的挑战。2018 年多学科国际共识对 cHCC-CCA 的命名法进行了定义,解决了该实体的关键问题。在这里,我们回顾了 cHCC-CCA 的历史争议,总结了 2018 年共识的关键要素,这些要素现在已被纳入 2019 年的世界卫生组织分类,并提出了一个简短的生存指南,以帮助外科病理学家在日常工作中面对 cHCC-CCA。